The announcement of presenting additional data from a clinical trial typically generates positive investor sentiment, especially in the biotech sector where trial results can significantly impact a company's valuation. If the data presented is positive, it could lead to increased investor confidence in Shattuck Labs' pipeline and future prospects, potentially driving up the stock price in the short term.